Revisiting C.G. Moertel's land of small tumors

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5005-5007

  Kvols, Larry K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CISPLATIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INDIUM 111; LUTETIUM 177; OCTREOTIDE; OCTREOTIDE LUTETIUM 177; OCTREOTIDE[DIETHYLENETRIAMINEPENTACETIC ACID INDIUM 111]; PACLITAXEL; PASIREOTIDE; PEGINTERFERON ALPHA2A; RADIOSENSITIZING AGENT; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOABLATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEPATIC ARTERY; HEPATIC ARTERY LIGATION; HUMAN; LIVER METASTASIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NOTE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HEPATIC ARTERY; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALIGNANT CARCINOID SYNDROME; RADIOPHARMACEUTICALS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 55549090724     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.2161     Document Type: Note

References (31)

1. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727-740, 1983
2. Moertel CG: Karnofsky Memorial Lecture: An odyssey in the land of small tumors. J Clin Oncol 5:1502-1522, 1987
3. Strosberg JR, Choi J, Cantor AB, et al: Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13:72-78, 2006
4. Moertel CG, Johnson CM, McKusick MA, et al: The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120:302-309, 1994
5. Sarmiento JM, Heywood G, Rubin J, et al: Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 197:29-37, 2003
6. Osborne DA, Zervos EE, Strosberg J, et al: Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13:572-581, 2006
7. Kvols LK, Martin JK, Marsh HM, et al: Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313:1229-1230, 1985
8. Kvols LK, Moertel CG, O'Connell MJ, et al: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663-666, 1986
9. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600-606, 1999
10. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973, 2004
11. Ruszniewski P, Ish-Shalom S, Wymenga M, et al: Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80:244-251, 2004
12. Schmid HA: Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74, 2008
13. Krenning EP, Bakker WH, Breeman WA, et al: Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242-244, 1989
14. Van Essen M, Krenning EP, De Jong M, et al: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723-734, 2007
15. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762, 2005
16. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130, 2008
17. van Essen M, Krenning EP, Kam BL, et al: Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35:743-748, 2008
18. Oberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309:129-133, 1983
19. Oberg K: Interferon in the management of neuroendocrine GEP-tumors: A review. Digestion 62:92-97, 2000 (suppl 1)
20. Kolby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687-693, 2003
21. Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696, 2003
22. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 23:4897-4904, 2005
23. Bukowski RM, Tangen CM, Peterson RF, et al: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: A Southwest Oncology Group study. Cancer 73:1505-1508, 1994
24. Kulke MH, Stuart K, Enzinger PC et al: Phase II study of temozolomide and thalidimide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006
25. Ansell SM, Pitot HC, Burch PA, et al: A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543-1548, 2001
26. Kulke MH, Kim H, Stuart K, et al: A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 22:353-359, 2004
27. Kulke MH, Kim H, Clark JW, et al: A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101:934-939, 2004
28. Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232, 1991
29. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316-1323, 2008
30. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
31. Yao JC, Phan A, Chang DZ, et al: Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2007 25:198s, 2007 (suppl; abstr 4503)